Obesity &Amp; Overweight, The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients
Conditions
Keywords
Coronary Flow Reserve, Semaglutide, Diabetes Mellitus
Brief summary
The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients. The main question it aims to answer is: Does semaglutide enhance coronary artery flow in diabetic and non-diabetic patients? Participants already planned taking semaglutide by an endocrine specialist as their treatment was assessed with CFR before and 3 months after.
Interventions
None listed
Sponsors
MEDICANA
Ekrem Bilal Karaayvaz
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
28 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients who were planned to start semaglutide.
Exclusion criteria
* Ischemic heart disease * Previous stent implantation or coronary bypass * Heart failure * Cardiomyopathies * Inflammatory diseases * Autoimmune rheumatic disease * Chronic liver and renal insufficiency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients who had acute coronary syndrome | From start of the study to 3 months after | Semaglutide is known for its beneficial effects on coronary vasculature. If a patient had myocardial infarction, this patient can no longer participate in study because the CFR ultimately changes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients who can not lose weight | From start to 3 months | Semaglutide is not only a diabetic drug but is also known for its weight loss properties. If the patient is unable to lose weight, additional information should be obtained as to why the drug is not working for this specific patient and should be removed from the study. |
Countries
Turkey (Türkiye)
Outcome results
None listed